UK News

April 12, 2011: Genzyme UK Announces Scottish Medicines Consortium Approval of Renvela® (sevelamer carbonate) for Use on the NHS in Scotland
April 8, 2010: New ‘Stem Cell Mobilisation’ Therapy Recommended by the All Wales Medicines Strategy Group
March 4, 2010: Genzyme Corporation’s generous benefaction to enable the creation of a key clinical academic post for Multiple Sclerosis, Neuroimmunological Diseases
January 18, 2010: New ‘Stem Cell Mobilisation’ Technology Accepted For Use by the Scottish Medicines Consortium
July 23, 2009: UK Scientist Wins Prestigious International Grant To Support Innovative Research In Renal Diseases
July 3, 2009: Andrew Lansley MP, Shadow Secretary of State for Health, sees cutting edge biotech science at Genzyme Europe Research in Cambridge

Highlight

Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

Sanofi-aventis and Genzyme Corporation announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion. Read the full corporate press release.

Contact Info:

Genzyme Therapeutics Ltd
4620 Kingsgate
Cascade Way
Oxford Business Park South
Oxford
OX4 2SU
Tel: +01865 405200
Fax: +01865 774172
Directions
Email

Genzyme Therapeutics Ltd, Genzyme Europe Research
310 Cambridge Science Park
Milton Road
Cambridge
CB4 0WG
Tel: +01223 394000
Fax: +01223 394190
Directions
Email

Genzyme Ltd, Haverhill Operations
12 Rookwood Way
Haverhill
Suffolk
CB9 8PU
Tel: +01440 703522
Fax: +01440 716269
Directions
Email